Categories
World

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

LY-CoV555, the lead antibody from the AbCellera and Lilly collaboration, has entered into human testing for the potential treatment of COVID-19.

  1. AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment